AB1076 Complex regional pain syndrome type 1: which treatment?. (12th June 2018)

• Record Type: Journal Article
• Authors: Sghir, M.; Salah, S.; Haj Salah, A.; Kessomtini, W.; Ben Salah, Z.
• Is Part Of: Annals of the rheumatic diseases. Volume 77(2018)Supplement 2
• Page Start: 1648
• Page End: 1648
• Publication Date: 2018-06-12
• Subjects: Rheumatism -- Periodicals; 616.723005
• DOI: 10.1136/annrheumdis-2018-eular.7477
• Languages: English
• ISSNs: 0003-4967

Abstract

Abstract : Background: The treatment of Complex Regional Pain Syndrome Type 1 (CRPS-I) is multidisciplinary. 1 It aims to minimise symptoms, pain, preserve functional ability and professional activity. Unfortunately, therapeutic possibilities are still very limited and there is no Gold standard. Objectives: The purpose of our work is to evaluate the efficiency of four therapeutic modalities in the management of CRPS-I. Methods: Retrospective study of 60 patients (21 men and 39 women) treated for CRPS-I. Four groups were identified according to therapeutic modalities used: rehabilitation alone (16 patients), Calcitonin associated with rehabilitation (15 patients), Bisphosphonates (BP) (Sodium Risedronate, 1 tablet per week, over an average duration of 1 month) associated with rehabilitation (20 patients) and Calcitonin in combination with BP and rehabilitation (9 patients). Results: The mean age of the patients was 51±16.5 years. The average time of treatment was 2 months and the average duration of follow-ups was 7 months. Traumatic origin was found in 88.3% of cases. Distal radius fractures (DRF) were the most incriminated (40% of cases). The evolution was judged on pain reduction, vasomotor signs and on functional improvement. For all etiologies combined, no statistically significant difference was found between the different groups (p=0.462). For patients with a DRF, a favourable outcome was noted in the BP group associated with rehabilitation in 85.7% of cases while it was only 42.9% for rehabilitation alone. Conclusions: Our study concludes that the different therapeutic modalities evaluated for the treatment of CRPS-I had an efficiency close to each other with a superiority of BP. Oral Sodium Risedronate could therefore be proposed as a treatment for CRPS-I without marketing authorisation (MA). Reference: [1] Hernández-Porras BC, Plancarte-Sánchez R, Alarcón-Barrios S, Sámano-García M. Complex regional pain syndrome: A review. Cirugía y Cirujanos (English Edition). 1 juill 2017;85(4):366–74. Disclosure of Interest: None declared